Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Relationship Between Metabolic Syndrome and Postmenopausal Breast Cancer
Journal Information
Vol. 98. Issue 9.
Pages 540-546 (November 2020)
Share
Share
Download PDF
More article options
ePub
Visits
1
Vol. 98. Issue 9.
Pages 540-546 (November 2020)
Original article
DOI: 10.1016/j.cireng.2020.06.009
Relationship Between Metabolic Syndrome and Postmenopausal Breast Cancer
Relación del síndrome metabólico con el cáncer de mama posmenopáusico
Visits
...
Ozgur Ekincia, Tunc Erena,
Corresponding author
drtunceren@gmail.com

Corresponding author.
, Melike Kurtoglu Yakicib, Aman Gapbarova, Muhammet Ali Aydemira, Zuhal Aydan Saglamb, Orhan Alimoglua
a Departamento de Cirugía General, Facultad de Medicina, Istanbul Medeniyet Üniversitesi, Estambul, Turkey
b Departamento de Medicina Familiar, Facultad de Medicina, Istanbul Medeniyet Üniversitesi, Estambul, Turkey
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (5)
Table 1. The Demographic Values of the Overall Group of Patients.
Table 2. Laboratory Parameters Among the Overall Group of Patients.
Table 3. Comparisons of Age and the Paramaters of Obesity Between the Study Groups.
Table 4. Comparisons of the Parameters of Diabetes and Metabolic Syndrome Between the Study Groups.
Table 5. The Distribution of Laboratory Findings Among the Study Groups.
Show moreShow less
Figures (1)
Abstract
Introduction

Metabolic syndrome is associated with an increased risk of diabetes mellitus (DM) and coronary heart disease. It may also be associated with a higher risk of some common cancers. The objective of this study was to determine the relationship between metabolic syndrome and breast cancer in postmenopausal women.

Methods

We present a prospective cohort study of postmenopausal women. This cohort was divided into two groups: the “benign diagnosis group”, including women who were studied after breast cancer screening; and the “malignant tumor group”, including patients with breast cancer that had been diagnosed by biopsy. Age, weight, height, body mass index (BMI), abdominal perimeter, serum glucose, LDL, HDL and insulin levels were analyzed as variables under study. The HOMA-IR homeostatic model formula was used to assess insulin resistance. The differences were considered statistically significant when P<.05.

Results

Two hundred women with a mean age of 61.5±9.6 (range: 37–93) were enrolled in the study, consisting of 150 (75%) patients with a benign diagnosis and 50 (25%) patients with a malignant tumor. BMI and abdominal perimeter were higher in the group with a malignant tumor (P<.05). The incidence of DM and metabolic syndrome was higher in the malignant tumor group (P<.005). In the malignant tumor group, much higher incidences correlated with fasting glycemic levels >100mg/dL, insulin levels >10mIU/L and HOMA-IR scores >2.7 (P<.05).

Conclusions

There is a relationship between metabolic syndrome and postmenopausal breast cancer. More studies are needed to establish methods for the prevention of breast cancer in women with metabolic syndrome.

Keywords:
Breast
Diabetes
Endocrine
General surgery
Cancer
Resumen
Introducción

El síndrome metabólico (SM) se asocia con un aumento del riesgo de diabetes mellitus (DM) y cardiopatía coronaria. El SM también puede estar asociado con un aumento del riesgo de algunos cánceres frecuentes. El objetivo de este estudio fue determinar la relación entre el SM y el cáncer de mama en mujeres posmenopáusicas.

Métodos

Estudio de cohortes prospectivo de mujeres posmenopáusicas. Dicha cohorte se dividió en dos grupos: el «grupo con un diagnóstico benigno», formado por mujeres a las cuales se les realizó un seguimiento por cribado del cáncer de mama, y el «grupo con un tumor maligno», formado por pacientes con cáncer de mama diagnosticado por biopsia. Se analizaron como variables a estudio la edad, peso, altura, índice de masa corporal (IMC), perímetro abdominal, glucosa sérica, LDL, HDL y niveles de insulina. Se utilizó la fórmula del modelo homeostático HOMA-IR para evaluar la resistencia a la insulina. Las diferencias se consideraron estadísticamente significativas cuando p<0,05.

Resultados

Doscientas mujeres con una media de edad de 61,5±9,6 años (rango: 37-93) se inscribieron en el estudio que consta de 150 (75%) pacientes en el grupo con un diagnóstico benigno y 50 (25%) pacientes en el grupo con un tumor maligno. El IMC y el perímetro abdominal fueron mayores en el grupo con un tumor maligno (p<0,05). La incidencia de DM y SM fue mayor en el grupo con un tumor maligno (p<0,005). En el grupo con un tumor maligno se detectaron incidencias mucho más altas en relación con los niveles glucémicos en ayunas >100mg/dl, los niveles de insulina >10mUI/l y puntuaciones en el HOMA-IR>2,7 (p<0,05).

Conclusiones

Existe relación entre el SM y el cáncer de mama posmenopáusico. Son necesarios más estudios para establecer métodos de protección para la prevención del cáncer de mama en mujeres con SM.

Palabras clave:
Mama
Diabetes
Endocrino
Cirugía general
Neoplasias

Article

These are the options to access the full texts of the publication Cirugía Española (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Cirugía Española (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos